

**Supplementary Table 1.** Demographics of all patient populations

Clinical manifestation	Patients with MASH	Patients with hepatic hemangioma
Age, years (mean±SD)	39.97±10.56	38.77±8.59
Gender, n (M/F)	25/14	10/21
BMI, kg/m <sup>2</sup>	42.41±4.36	22.38±2.42
Hyperlipidemia (%)	27 (69)	0 (0)
Laboratory tests (mean±SD)		
ALT, U/L	126.93±35.26	23.57±4.66
AST, U/L	68.94±26.25	21.84±5.21
ALP, U/L	76.73±18.62	42.31±13.30
γ-GT, U/L	68.96±14.49	28.67±8.53
TG, U/L	2.09±0.53	1.15±0.19
TC, U/L	5.15±0.52	3.21±0.42
Platelet, 109/L	198.81±46.32	258.02±58.25
FIB-4	2.23±0.63	0.93±0.45
Histological characteristics		
NAS (mean±SD)	6.05±0.96	0
Steatosis grade 1/2/3	13/10/16	
Lobular inflammation 0/1/2/3	11/15/8/5	
Ballooning 0/1/2	8/18/13	
Fibrosis stage 0/1/2/3/4	5/10/9/12/3	

BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; γ-GT, γ-glutamyl-transferase; TG, triglyceride; TC, total cholesterol; FIB-4, fibrosis-4 score; NAS, NAFLD activity score.